Fly on the wall, buyout chatter…

Quote













anonymous said:
Like you even know anything. Stock will be $100 in a year based on growth potential
Click to expand...
Well it’s called chatter for a reason… your not yet approved and PDUFA date is mid 2025… there is modest growth till you launch with full year impact in 2026. Buyouts on phase 3 tradings in advance of approval is not uncommon but a risk for suitor… at current levels your stock price reflect supposition… and the fact there’s no wrinkles in NDA filing.
 


anonymous said:
Well it’s called chatter for a reason… your not yet approved and PDUFA date is mid 2025… there is modest growth till you launch with full year impact in 2026. Buyouts on phase 3 tradings in advance of approval is not uncommon but a risk for suitor… at current levels your stock price reflect supposition… and the fact there’s no wrinkles in NDA filing.
Click to expand...
Not sure why they would sell at $78 a share. The stock will be double that in two years
 








Insmed stock at $100/$150 isn't too high for an acquisition. Celgene was $102 when it was acquired. Biogen was over $190. And any offer must be presented to the Board regardless.
 


anonymous said:
Insmed stock at $100/$150 isn't too high for an acquisition. Celgene was $102 when it was acquired. Biogen was over $190. And any offer must be presented to the Board regardless.
Click to expand...
At least these are real facts. If we are purchased, expect more than current stock price. Why spend your time speculating on something you have no control over?
 



Write your reply...
Top Bottom
Back
Quote